Evidence map›Paper›PMID 34526403›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2021

Posttranslational modifications by ADAM10 shape myeloid antigen-presenting cell homeostasis in the splenic marginal zone.

Nathalie Diener, Jean-Fred Fontaine, Matthias Klein, Thomas Hieronymus, Florian Wanke, Florian C Kurschus, Andreas Ludwig, Carl Ware, Paul Saftig, Tobias Bopp and 2 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Nathalie DienerInstitute for Molecular Medicine, Paul Klein Center for Immune Intervention, University Medical Center of the Johannes Gutenberg-University, 55131 Mainz, Germany.ORCID 0000-0002-9098-735X
Jean-Fred FontaineiOME Computational Biology and Data Mining, Johannes Gutenberg-University, 55128 Mainz, Germany.ORCID 0000-0002-1101-4091
Matthias KleinInstitute for Immunology, Paul Klein Center for Immune Intervention, University Medical Center of the Johannes Gutenberg-University, 55131 Mainz, Germany.
Thomas HieronymusDepartment of Cell Biology, Institute for Biomedical Engineering, Rheinisch-Westfälische Technische Hochschule Aachen, University Medical Center, 52074 Aachen, Germany.
Florian WankeInstitute for Molecular Medicine, Paul Klein Center for Immune Intervention, University Medical Center of the Johannes Gutenberg-University, 55131 Mainz, Germany.
Florian C KurschusInstitute for Molecular Medicine, Paul Klein Center for Immune Intervention, University Medical Center of the Johannes Gutenberg-University, 55131 Mainz, Germany.
Andreas LudwigInstitute of Pharmacology and Toxicology, Rheinisch-Westfälische Technische Hochschule Aachen, University Medical Center, 52074 Aachen, Germany.
Carl WareInfectious and Inflammatory Diseases Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037.
Paul SaftigInstitute of Biochemistry, Christian-Albrechts-University Kiel, 24098 Kiel, Germany.
Tobias BoppInstitute for Immunology, Paul Klein Center for Immune Intervention, University Medical Center of the Johannes Gutenberg-University, 55131 Mainz, Germany.ORCID 0000-0002-3232-8065
Björn E ClausenInstitute for Molecular Medicine, Paul Klein Center for Immune Intervention, University Medical Center of the Johannes Gutenberg-University, 55131 Mainz, Germany; bclausen@uni-mainz.de r.backer@uni-mainz.de.ORCID 0000-0002-2484-7842
Ronald A BackerInstitute for Molecular Medicine, Paul Klein Center for Immune Intervention, University Medical Center of the Johannes Gutenberg-University, 55131 Mainz, Germany; bclausen@uni-mainz.de r.backer@uni-mainz.de.ORCID 0000-0003-1464-3755
Johannes Gutenberg University Mainz · DERWTH Aachen University · DEChristian-Albrechts-Universität zu Kiel · DESanford Burnham Prebys Medical Discovery Institute · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The spleen contains phenotypically and functionally distinct conventional dendritic cell (cDC) subpopulations, termed cDC1 and cDC2, which each can be divided into several smaller and less well-characterized subsets. Despite advances in understanding the complexity of cDC ontogeny by transcriptional programming, the significance of posttranslational modifications in controlling tissue-specific cDC subset immunobiology remains elusive. Here, we identified the cell-surface-expressed A-disintegrin-and-metalloproteinase 10 (ADAM10) as an essential regulator of cDC1 and cDC2 homeostasis in the splenic marginal zone (MZ). Mice with a CD11c-specific deletion of ADAM10 (ADAM10

Indexed as

ADAM10 ProteinAmyloid Precursor Protein SecretasesAnimalsAntigen-Presenting CellsCD11c AntigenCell DifferentiationCell ProliferationDendritic CellsFemaleHomeostasisLymphoid TissueMacrophagesMaleMembrane ProteinsMiceMice, Inbred C57BLADAM10 ProteinAdam10 protein, mouseAmyloid Precursor Protein SecretasesCD11c AntigenMembrane ProteinsPhosphatidylinositol 3-KinasesA-disintegrin-and-metalloproteinase 10conventional dendritic cellsmarginal metallophilic macrophagesNotch signalingsplenic marginal zone

Identifiers

PMID34526403
PMCPMC8463803
OpenAlexW3199476121

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.